-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to news from the National Medical Insurance Administration, Zhejiang Province notified Harbin Yuheng Pharmaceutical Co.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
According to the judgment of the local court in Zhejiang, Harbin Yuheng Pharmaceutical Co.
, Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
, Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
According to reports, the National Medical Insurance Bureau will organize provincial medical security departments and centralized pharmaceutical procurement agencies to accelerate the implementation of the credit evaluation system nationwide, and target the recently exposed pharmaceutical companies that have excessively high sales expenses and false expense statements that are contrary to integrity.
Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
According to news from the National Medical Insurance Administration, Zhejiang Province notified Harbin Yuheng Pharmaceutical Co.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
According to the judgment of the local court in Zhejiang, Harbin Yuheng Pharmaceutical Co.
, Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
, Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
According to reports, the National Medical Insurance Bureau will organize provincial medical security departments and centralized pharmaceutical procurement agencies to accelerate the implementation of the credit evaluation system nationwide, and target the recently exposed pharmaceutical companies that have excessively high sales expenses and false expense statements that are contrary to integrity.
Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
According to news from the National Medical Insurance Administration, Zhejiang Province notified Harbin Yuheng Pharmaceutical Co.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
, Ltd.
of the credit evaluation results of Lugua Polypeptide Injection and suspended online transactions.
This is the first case in the country where the credit evaluation has reached a "serious" rating.
The case indicates that the credit evaluation system has entered a new stage of substantive effects.
According to the judgment of the local court in Zhejiang, Harbin Yuheng Pharmaceutical Co.
, Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
pharmnet. , Ltd.
’s Lugua Polypeptide Injection was involved in commercial bribery of kickbacks in Zhejiang Province.
The amount was relatively large.
According to the medical price and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement system, the enterprise was concentrated in Zhejiang Province’s medicine.
The price of the procurement market and the level of untrustworthy recruitment were assessed as "serious", and the company's Lugua Polypeptide Injection was suspended online trading in Zhejiang Province.
com.
cn/news/yyzb/" target="_blank">Bidding pharmnet.
com.
cn/news/yyzb/" target="_blank">procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> bidding biddingpharmnet.
com.
cn/news/yyzb/" target="_blank"> procurement procurement
In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
Medicine Medicine Medicine According to reports, the National Medical Insurance Bureau will organize provincial medical security departments and centralized pharmaceutical procurement agencies to accelerate the implementation of the credit evaluation system nationwide, and target the recently exposed pharmaceutical companies that have excessively high sales expenses and false expense statements that are contrary to integrity.
Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
Enterprise business enterprise Regarding the issues of operation and fair pricing, we will continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote pharmaceutical companies to set prices in accordance with the principles of fairness, reasonableness, honesty and credibility, and conformity with quality and price.
